Impaired Color Recognition in HCN1 Epilepsy: A Single Case Report

Chaseley E Mckenzie1, Chen-Jui Ho2, Ian C Forster1

  • 1Early Development Division, Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia.

Insights

A novel HCN1 gene variant, E246A, is linked to epilepsy and developmental delay. This finding highlights potential visual deficits, like color discrimination issues, in patients with HCN1-related disorders.

Area of Science:

  • Neuroscience
  • Genetics
  • Ophthalmology

Background:

  • Pathogenic variants in the HCN1 gene are associated with various epilepsy syndromes, including developmental and epileptic encephalopathies.
  • HCN1 channels are highly expressed in retinal photoreceptors, suggesting a role in visual function.

Purpose of the Study:

  • To report a novel de novo HCN1 variant (E246A) in a child with epilepsy and developmental delay.
  • To investigate the functional consequences of the HCN1 E246A variant.
  • To explore the potential link between HCN1 variants and visual deficits, specifically color discrimination.

Main Methods:

  • Clinical case description of a child with epilepsy and mild developmental delay.
  • Parental report of visual deficits, including color discrimination difficulties.
  • In vitro functional analysis of the HCN1 E246A variant's biophysical properties.

Main Results:

  • A novel de novo HCN1 variant, E246A, was identified in the patient.
  • Functional analysis revealed a gain-of-function effect for the E246A variant, characterized by a right shift in voltage dependence of activation and slowed activation/deactivation rates.
  • The patient exhibited difficulties with color discrimination, suggesting a visual deficit.

Conclusions:

  • The HCN1 E246A variant's gain-of-function properties support its role in disease causation.
  • This case suggests a potential link between HCN1 pathogenic variants and visual dysfunction, including impaired color discrimination.
  • Ophthalmological monitoring, particularly for color vision, is recommended for patients with HCN1-related disorders.